SIGNAL PEPTIDE SCREENING FOR mAbs AND BITE GENERATION USING A CHO PLATFORM
Dicembre 10 @ 11:30 AM - 12:30 PM
Goals: to present the services provided by Menarini Biotech to support development of biotherapeutic molecules. The webinar will be focused on the workflow for the Signal Peptides screening studies applied to the production of two different kinds of therapeutic proteins (mAb and BITE).
Recipients of the course
Companies, partners, potential clients involved in the development and manufacturing of therapeutic drugs starting from cell lines.
What we learn from the course
- Services supplied by MENARINI Biotech as CDMO
- Approach for evaluation of Signal Peptides impact on molecules productivity
- Comparison between different analytical methods for the verification of transfection efficiency
Speakers
- Lavinia Nardinocchi, Cell Line Development specialist Menarini Biotech, Pomezia (Rome), Italy. Lavinia Nardinocchi took the Master degree in Medical, Molecular and Cellular Biotechnology and a PhD in Molecular Medicine from the University of Rome “La Sapienza”(Italy). For 10 years she worked in the field of cancer research, in.2015 she started working in MBH as an Upstream lab technician both in the development department and in the GMP production. Since 2022 she has been holding the role of Cell Line Development Specialist in Process Development Upstream Group. In recent years she has acquired strong skills in the development of the Upstream process and in cell line development.
- Alessandra Mariani, Analytical Development Bioassays specialist Menarini Biotech, Pomezia (Rome), Italy. Alessandra, took the Master Degree in Medical Biotechnology at University of Perugia and the PhD in Life Science cellular physiology at GSK Vaccines- University of Siena. In 2015 she joined Menarini Biotech, in Pomezia (Rome). Starting as laboratory technician in the Analytical Development Department, she is currently holding the position of Analytical Development specialist as Subject Matter Expert (SME) in the Immuno-Bioassays field. Alessandra’s experience in the R&D of pharma companies was mainly focused on polyclonal and monoclonal antibodies, in particular on the development of immunoassays, kinetic assays and cell-based assays for antibody characterization.
